$CYRX
Cryoport, Inc.

2022 Q3 Form 10-Q Financial Statement

#000141057822002045 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2021 Q4
Revenue $60.46M $64.15M $56.44M
YoY Change 6.65% 14.17% 16.71%
Cost Of Revenue $34.05M $35.32M $33.33M
YoY Change 2.61% 14.7% 17.06%
Gross Profit $26.42M $28.84M $23.11M
YoY Change 12.35% 13.53% 16.18%
Gross Profit Margin 43.69% 44.95% 40.95%
Selling, General & Admin $30.24M $30.56M $27.59M
YoY Change 26.5% 23.8% 5.09%
% of Gross Profit 114.45% 105.98% 119.35%
Research & Development $3.985M $3.522M $3.890M
YoY Change -4.85% -21.07% 11.46%
% of Gross Profit 15.08% 12.21% 16.83%
Depreciation & Amortization $5.786M $5.480M $5.303M
YoY Change 12.2% 10.77% -28.05%
% of Gross Profit 21.9% 19.0% 22.94%
Operating Expenses $34.22M $34.09M $31.48M
YoY Change 21.83% 16.93% 5.84%
Operating Profit -$7.803M -$5.247M -$8.362M
YoY Change 70.52% 39.99% -15.08%
Interest Expense $1.609M $1.586M $509.0K
YoY Change 35.32% 36.25% -259.06%
% of Operating Profit
Other Income/Expense, Net $2.544M -$3.566M -$1.354M
YoY Change -374.73% 212.26% -7.89%
Pretax Income -$5.259M -$8.813M -$261.0M
YoY Change -4.42% 80.22% 2143.87%
Income Tax $57.00K $364.0K -$876.0K
% Of Pretax Income
Net Earnings -$5.316M -$9.177M -$260.1M
YoY Change -18.54% 70.29% 2155.73%
Net Earnings / Revenue -8.79% -14.3% -460.82%
Basic Earnings Per Share -$0.15 -$0.23 -$5.46
Diluted Earnings Per Share -$0.15 -$0.23 -$5.413M
COMMON SHARES
Basic Shares Outstanding 48.49M 48.79M 46.30M
Diluted Shares Outstanding 48.52M 48.79M

Balance Sheet

Concept 2022 Q3 2022 Q2 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $529.5M $550.6M $628.8M
YoY Change 51.52% 57.58% 573.95%
Cash & Equivalents $30.72M $37.03M $139.1M
Short-Term Investments $500.7M $521.9M $601.0M
Other Short-Term Assets $10.64M $8.250M $8.804M
YoY Change 18.77% -34.39% -26.02%
Inventory $24.54M $23.07M $16.50M
Prepaid Expenses
Receivables $44.42M $43.90M $39.41M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $609.1M $625.8M $693.5M
YoY Change 48.43% 51.99% 371.28%
LONG-TERM ASSETS
Property, Plant & Equipment $57.68M $54.01M $49.03M
YoY Change 34.6% 42.84% 63.23%
Goodwill $147.5M $145.2M $147.0M
YoY Change 0.74% -1.21% 1.15%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.568M $2.523M $419.0K
YoY Change 1525.32% 232.41% -47.23%
Total Long-Term Assets $424.7M $420.5M $419.5M
YoY Change 2.58% 1.68% 3.51%
TOTAL ASSETS
Total Short-Term Assets $609.1M $625.8M $693.5M
Total Long-Term Assets $424.7M $420.5M $419.5M
Total Assets $1.034B $1.046B $1.113B
YoY Change 25.4% 26.78% 101.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $27.44M $31.09M $28.58M
YoY Change -6.14% 5.97% 15.25%
Accrued Expenses $11.63M $11.01M $13.45M
YoY Change 1.42% 32.59% 38.7%
Deferred Revenue $549.0K $818.0K $547.0K
YoY Change 78.25% 78.21% 22.92%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.010M $1.132M $61.00K
YoY Change 1555.74% 1958.18% -39.0%
Total Short-Term Liabilities $40.73M $44.05M $42.65M
YoY Change -0.84% 15.44% 21.77%
LONG-TERM LIABILITIES
Long-Term Debt $406.6M $405.8M $405.3M
YoY Change 249.02% 248.68% 248.2%
Other Long-Term Liabilities $455.0K $378.0K $349.0K
YoY Change 207.43% 114.77% 98.3%
Total Long-Term Liabilities $455.0K $378.0K $349.0K
YoY Change 207.43% 114.77% 98.3%
TOTAL LIABILITIES
Total Short-Term Liabilities $40.73M $44.05M $42.65M
Total Long-Term Liabilities $455.0K $378.0K $349.0K
Total Liabilities $478.1M $477.9M $471.1M
YoY Change 169.85% 169.58% 177.62%
SHAREHOLDERS EQUITY
Retained Earnings -$503.8M -$498.5M -$467.5M
YoY Change 142.84% 148.08% 143.49%
Common Stock $1.086B $1.082B $1.100B
YoY Change 28.35% 28.54% 94.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $555.7M $568.4M $641.8M
YoY Change
Total Liabilities & Shareholders Equity $1.034B $1.046B $1.113B
YoY Change 25.4% 26.78% 101.48%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2021 Q4
OPERATING ACTIVITIES
Net Income -$5.316M -$9.177M -$260.1M
YoY Change -18.54% 70.29% 2155.73%
Depreciation, Depletion And Amortization $5.786M $5.480M $5.303M
YoY Change 12.2% 10.77% -28.05%
Cash From Operating Activities $982.0K -$7.011M $2.614M
YoY Change -88.94% -366.98% -126.89%
INVESTING ACTIVITIES
Capital Expenditures -$5.751M -$5.386M -$8.544M
YoY Change -37.49% 27.84% 92.87%
Acquisitions
YoY Change
Other Investing Activities -$114.0K -$58.60M -$187.4M
YoY Change -99.36% 119.56% -50.5%
Cash From Investing Activities -$5.865M -$63.99M -$196.0M
YoY Change -78.28% 107.05% -48.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -459.0K -25.36M 288.6M
YoY Change -118.43% -1444.64% 8.3%
NET CHANGE
Cash From Operating Activities 982.0K -7.011M 2.614M
Cash From Investing Activities -5.865M -63.99M -196.0M
Cash From Financing Activities -459.0K -25.36M 288.6M
Net Change In Cash -5.342M -96.36M 95.22M
YoY Change -65.85% 265.1% -175.37%
FREE CASH FLOW
Cash From Operating Activities $982.0K -$7.011M $2.614M
Capital Expenditures -$5.751M -$5.386M -$8.544M
Free Cash Flow $6.733M -$1.625M $11.16M
YoY Change -62.75% -123.76% -310.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Address Line1
EntityAddressAddressLine1
112 Westwood Place, Suite 350
dei Entity Address City Or Town
EntityAddressCityOrTown
Brentwood
dei Entity Central Index Key
EntityCentralIndexKey
0001124524
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48792559
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45757532
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49467691
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44786403
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48792559
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45757532
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49467691
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44786403
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49616154
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48482502
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34632
dei Entity Registrant Name
EntityRegistrantName
CRYOPORT, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0313393
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45757532
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8810000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2488000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49467691
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44786403
dei Entity Address State Or Province
EntityAddressStateOrProvince
TN
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-8605000
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
37027
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9177000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5389000
dei City Area Code
CityAreaCode
949
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48489803
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37034000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
139101000
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
513584000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
489698000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
43903000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8813000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4890000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21876000
us-gaap Net Income Loss
NetIncomeLoss
-22581000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
39412000
CY2022Q2 us-gaap Inventory Net
InventoryNet
23070000
CY2021Q4 us-gaap Inventory Net
InventoryNet
16501000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7378000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8250000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8804000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
364000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
499000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
625841000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
693516000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
705000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1538000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
54011000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9177000
us-gaap Net Income Loss
NetIncomeLoss
-8916000
CY2022Q2 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
5310000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
49029000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5389000
CY2021Q2 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
432000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22740000
us-gaap Net Income Loss
NetIncomeLoss
-22581000
us-gaap Net Income Loss
NetIncomeLoss
-8916000
us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
19374000
us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
1178000
CY2022Q2 cyrx Paid In Kind Dividend On Series C Convertible Preferred Stock Value
PaidInKindDividendOnSeriesCConvertiblePreferredStockValue
2000000
CY2021Q2 cyrx Paid In Kind Dividend On Series C Convertible Preferred Stock Value
PaidInKindDividendOnSeriesCConvertiblePreferredStockValue
2000000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20675000
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
196013000
cyrx Paid In Kind Dividend On Series C Convertible Preferred Stock Value
PaidInKindDividendOnSeriesCConvertiblePreferredStockValue
4000000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
201427000
cyrx Paid In Kind Dividend On Series C Convertible Preferred Stock Value
PaidInKindDividendOnSeriesCConvertiblePreferredStockValue
4196000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-14000
CY2021Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-8000
CY2022Q2 us-gaap Goodwill
Goodwill
145201000
CY2021Q4 us-gaap Goodwill
Goodwill
146954000
CY2022Q2 us-gaap Deposits Assets
DepositsAssets
926000
CY2021Q4 us-gaap Deposits Assets
DepositsAssets
950000
CY2022Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1597000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
419000
CY2022Q2 us-gaap Assets
Assets
1046329000
CY2021Q4 us-gaap Assets
Assets
1112970000
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
31086000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
28583000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-46000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8354000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9912000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
818000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
547000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2656000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3542000
CY2022Q2 us-gaap Notes Payable Current
NotesPayableCurrent
1079000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
53000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
61000
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
44046000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11177000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7389000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
42645000
CY2022Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
405436000
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
404171000
CY2022Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
374000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
1086000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21106000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18144000
CY2022Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3745000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4018000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
378000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
349000
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
2820000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
729000
CY2022Q2 us-gaap Liabilities
Liabilities
477905000
CY2021Q4 us-gaap Liabilities
Liabilities
471142000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48482502
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49616154
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
49000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
50000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1081747000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1100287000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-498471000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-467541000
CY2022Q2 cyrx Accumulated Other Comprehensive Income Loss
AccumulatedOtherComprehensiveIncomeLoss
-29176000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-38000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-7558000
CY2021Q4 cyrx Accumulated Other Comprehensive Income Loss
AccumulatedOtherComprehensiveIncomeLoss
-1243000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
568424000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
641828000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1046329000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26581000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13112000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1112970000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
644000
CY2022Q2 us-gaap Revenues
Revenues
64153000
CY2021Q2 us-gaap Revenues
Revenues
56191000
us-gaap Revenues
Revenues
116455000
us-gaap Revenues
Revenues
109475000
CY2021Q2 us-gaap Interest Expense
InterestExpense
1164000
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
35315000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Interest Expense
InterestExpense
3077000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48792559
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
30789000
us-gaap Cost Of Revenue
CostOfRevenue
65276000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3566000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1142000
dei Local Phone Number
LocalPhoneNumber
470-2300
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
CYRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
us-gaap Cost Of Revenue
CostOfRevenue
59523000
CY2022Q2 us-gaap Gross Profit
GrossProfit
28838000
CY2021Q2 us-gaap Gross Profit
GrossProfit
25402000
us-gaap Gross Profit
GrossProfit
51179000
us-gaap Gross Profit
GrossProfit
49952000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30563000
us-gaap Interest Expense
InterestExpense
2373000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9045000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24688000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
57185000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
46076000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3522000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4462000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7060000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8766000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
34085000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
29150000
us-gaap Operating Expenses
OperatingExpenses
64245000
us-gaap Operating Expenses
OperatingExpenses
54842000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5247000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3748000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13066000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4890000
CY2022Q2 us-gaap Investment Income Net
InvestmentIncomeNet
2048000
CY2021Q2 us-gaap Investment Income Net
InvestmentIncomeNet
368000
us-gaap Investment Income Net
InvestmentIncomeNet
3312000
us-gaap Investment Income Net
InvestmentIncomeNet
766000
CY2022Q2 us-gaap Interest Expense
InterestExpense
1586000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4028000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-346000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-881000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-27933000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4276000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22031000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5169000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-3136000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-12854000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50514000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13192000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
647275000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-5389000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
220000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
220000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4025000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1898000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
648029000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
609434000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-9177000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-12854000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5258000
CY2022Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
479000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1581000
CY2022Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
25000000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
284000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
568424000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
382698000
us-gaap Profit Loss
ProfitLoss
-8916000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4276000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7003000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
11000
cyrx Adjustments To Additional Paid In Capital Conversion Costs
AdjustmentsToAdditionalPaidInCapitalConversionCosts
-1800000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
269825000
cyrx Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
3484000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
648029000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
641828000
us-gaap Profit Loss
ProfitLoss
-22581000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-27933000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9383000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
479000
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
33349000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
597000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
568424000
us-gaap Net Income Loss
NetIncomeLoss
-22581000
us-gaap Net Income Loss
NetIncomeLoss
-8916000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10845000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9787000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1286000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
496000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-8556000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-156000
cyrx Realized Loss On Investments In Equity Securities
RealizedLossOnInvestmentsInEquitySecurities
80000
cyrx Realized Loss On Investments In Equity Securities
RealizedLossOnInvestmentsInEquitySecurities
85000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9383000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7015000
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-304000
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-113000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
35000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
215000
cyrx Excess And Obsolete Inventory
ExcessAndObsoleteInventory
546000
us-gaap Proceeds From Insurance Premiums Collected
ProceedsFromInsurancePremiumsCollected
6311000
us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
4291000
us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
5590000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
9476000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1138000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1043000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
512000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-27000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-230000
cyrx Right Of Use Asset Obtained In Exchange For Operating Leases Liability
RightOfUseAssetObtainedInExchangeForOperatingLeasesLiability
-27000
cyrx Right Of Use Asset Obtained In Exchange For Operating Leases Liability
RightOfUseAssetObtainedInExchangeForOperatingLeasesLiability
-220000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4283000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4983000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-661000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-151000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-33409000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
14000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-481000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
105000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6487000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3364000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9060000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6705000
cyrx Payments For Proceeds From Insurance Proceeds For Loss From Fixed Assets
PaymentsForProceedsFromInsuranceProceedsForLossFromFixedAssets
-3000000
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
564000
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
449000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
136611000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
241993000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
84760000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
8000000
cyrx Payments To Acquire Cell And Co
PaymentsToAcquireCellAndCo
2107000
cyrx Payments To Acquire Ctsa And Fair Gate
PaymentsToAcquireCtsaAndFairGate
5019000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
358000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
109000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-60940000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-246275000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
597000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3483000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
33349000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
639000
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
18000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
269825000
cyrx Repayment Of Finance Lease Liabilities
RepaymentOfFinanceLeaseLiabilities
32000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
273276000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1231000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-153000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-102067000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23484000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
139101000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36873000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37034000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60357000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
765000
cyrx Cost Of Series C Preferred Stock Conversion Included In Additional Paid In Capital And Accounts Payable And Accrued Liabilities
CostOfSeriesCPreferredStockConversionIncludedInAdditionalPaidInCapitalAndAccountsPayableAndAccruedLiabilities
1800000
cyrx Goodwill Adjustment Included In Deferred Tax Liability
GoodwillAdjustmentIncludedInDeferredTaxLiability
877000
cyrx Goodwill Adjustment Included In Fixed Assets
GoodwillAdjustmentIncludedInFixedAssets
71000
cyrx Acquiree Working Capital Settlement Included In Goodwill And Accounts Payable
AcquireeWorkingCapitalSettlementIncludedInGoodwillAndAccountsPayable
500000
cyrx Note Valuation Adjustment Included In Note Payable And Goodwill
NoteValuationAdjustmentIncludedInNotePayableAndGoodwill
275000
cyrx Non Cash Net Unrealized Gain Loss On Available For Sale Securities
NonCashNetUnrealizedGainLossOnAvailableForSaleSecurities
-19374000
cyrx Non Cash Net Unrealized Gain Loss On Available For Sale Securities
NonCashNetUnrealizedGainLossOnAvailableForSaleSecurities
-1178000
cyrx Reclassification Of Realized Gain On Available For Sale Debt Securities To Earnings
ReclassificationOfRealizedGainOnAvailableForSaleDebtSecuritiesToEarnings
-46000
cyrx Reclassification Of Realized Gain On Available For Sale Debt Securities To Earnings
ReclassificationOfRealizedGainOnAvailableForSaleDebtSecuritiesToEarnings
-38000
cyrx Paid In Kind Dividend On Series C Convertible Preferred Stocks Value
PaidInKindDividendOnSeriesCConvertiblePreferredStocksValue
4000000
cyrx Paid In Kind Dividend On Series C Convertible Preferred Stocks Value
PaidInKindDividendOnSeriesCConvertiblePreferredStocksValue
4196000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
397000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3868000
cyrx Non Cash Activity Of Common Stock Issued For Cell Co Acquisition
NonCashActivityOfCommonStockIssuedForCellCoAcquisition
479000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1200000
CY2022Q2 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 2. Nature of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cryoport serves the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the biopharma/pharma, animal health, and reproductive medicine markets. Our mission is to support life and health worldwide and we are continuously developing, implementing, and leveraging our supply chain platform, which is designed to deliver comprehensive, unparalleled, highly differentiated temperature-controlled logistics, packaging, storage, cryogenic systems, informatics, and related services for life science products, regenerative medicine, cellular therapies, and treatments that require unique, specialized cold chain management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 1, 2020, the Company completed both the acquisition of MVE Biological Solutions (the “MVE Acquisition”) and the acquisition of CRYOPDP (the “CRYOPDP Acquisition”). In addition, in the second quarter of 2021, the Company completed the acquisitions of Critical Transport Solutions Australia (CTSA) in Australia and F-airGate in Belgium to further enhance CRYOPDP’s existing global temperature-controlled supply chain capabilities in the APAC (Asia-Pacific) and EMEA (Europe, the Middle East, and Africa) regions. Also, in April 2022, the Company completed the acquisition of Cell&amp;Co BioServices (Cell&amp;Co) in Clermont-Ferrand, France (See Note 4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subsequent to quarter end, in July 2022, the Company completed the acquisition of Polar Expres in Madrid, Spain which provides temperature-controlled logistics solutions dedicated to the life sciences industry and Cell Matters in Liège, Belgium which provides cryo-process optimization, cryoprocessing, and cryopreservation solutions to the life sciences industry (See Note 15).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.”</p>
cyrx Maturity Period Of Highly Liquid Investments
MaturityPeriodOfHighlyLiquidInvestments
P90D
CY2022Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, fair value of short-term investments, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, intangible asset useful lives and amortization methods, allowance for inventory obsolescence, contingent consideration liability, equity-based instruments, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Future events, including the extent and the duration of the COVID-19 related economic impacts, and their effects cannot be predicted with certainty, and, accordingly the Company’s accounting estimates require the exercise of judgment.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”). Primarily all of our cash, cash equivalents and short-term investments at June 30, 2022 were in excess of amounts insured by the FDIC and SIPC. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure. We manage such risks in our portfolio by investing in highly liquid, highly-rated instruments, and limit investing in long-term maturity instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our investment policy requires that purchased instruments in marketable securities may only be in highly-rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer.</p>
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1200000
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P5Y
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
cyrx Tax Examination Period For Foreign Subsidiaries
TaxExaminationPeriodForForeignSubsidiaries
P3Y
CY2020Q2 cyrx Statutory Credit Usage Limit For Research And Development For Tax Relief
StatutoryCreditUsageLimitForResearchAndDevelopmentForTaxRelief
5000000
CY2021Q1 us-gaap Charity Care Reimbursements Received
CharityCareReimbursementsReceived
1000000
cyrx Revenue Practical Expedient Remaining Performance Obligation.
RevenuePracticalExpedientRemainingPerformanceObligation.
true
CY2022Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
500000
CY2021Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
500000
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
800000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
500000
CY2022Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
400000
CY2021Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
200000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
600000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
300000
CY2021Q2 cyrx Paid In Kind Dividend On Series C Convertible Preferred Stock Value
PaidInKindDividendOnSeriesCConvertiblePreferredStockValue
2000000
CY2022Q2 us-gaap Revenues
Revenues
64153000
CY2021Q2 us-gaap Revenues
Revenues
56191000
us-gaap Revenues
Revenues
116455000
us-gaap Revenues
Revenues
109475000
CY2022Q2 us-gaap Revenues
Revenues
64153000
CY2021Q2 us-gaap Revenues
Revenues
56191000
us-gaap Revenues
Revenues
116455000
us-gaap Revenues
Revenues
109475000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9177000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5389000
us-gaap Net Income Loss
NetIncomeLoss
-22581000
us-gaap Net Income Loss
NetIncomeLoss
-8916000
CY2022Q2 cyrx Paid In Kind Dividend On Series C Convertible Preferred Stock Value
PaidInKindDividendOnSeriesCConvertiblePreferredStockValue
2000000
cyrx Paid In Kind Dividend On Series C Convertible Preferred Stock Value
PaidInKindDividendOnSeriesCConvertiblePreferredStockValue
4000000
cyrx Paid In Kind Dividend On Series C Convertible Preferred Stock Value
PaidInKindDividendOnSeriesCConvertiblePreferredStockValue
4196000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11177000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7389000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26581000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13112000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48792559
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45757532
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49467691
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44786403
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13742180
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16288578
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14131016
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16341257
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-8600000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3100000
CY2021Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
193000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reclassification</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior year amounts in sales and marketing expense have been reclassified to selling, general and administrative expense to conform to the current period presentation, which reflects how the Company tracks operating costs. These reclassifications had no effect on the previously reported net loss.</p>
CY2022Q2 cyrx Business Combination Prior Period Adjustment Deferred Tax
BusinessCombinationPriorPeriodAdjustmentDeferredTax
800000
CY2022Q2 us-gaap Cash
Cash
28761000
CY2021Q4 us-gaap Cash
Cash
27788000
CY2022Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
8273000
CY2021Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
111313000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37034000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
139101000
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
513584000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
489698000
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
550618000
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
628799000
CY2022Q2 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
430398000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
19328000
CY2022Q2 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
411070000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
77695000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
76845000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
352703000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
334225000
CY2022Q2 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
430398000
CY2022Q2 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
411070000
CY2021Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
383547
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3867
CY2021Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
379692
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
39081
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
39035
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
328776
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
325047
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
15690
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
15610
CY2021Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
383547
CY2021Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
379692
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
-80000.00
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
-40000.00
CY2022Q2 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
102500000
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6441000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3985000
CY2022Q2 us-gaap Inventory Net
InventoryNet
23070000
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-8556000
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-156000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-8556000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-156000
CY2021Q2 us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
2
CY2022Q2 us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
2
CY2022Q2 cyrx Business Combination Contingent Consideration Liability Fair Value Disclosure
BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure
2800000
CY2021Q4 us-gaap Inventory Net
InventoryNet
16501000
CY2022Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
16244000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
11846000
CY2022Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
385000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
670000
CY2021Q4 us-gaap Goodwill
Goodwill
146954000
CY2020Q4 us-gaap Goodwill
Goodwill
145282000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-4369000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-483000
CY2022Q2 us-gaap Goodwill
Goodwill
145201000
CY2021Q2 us-gaap Goodwill
Goodwill
146974000
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
228973000
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
32960000
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
196013000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
224839000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
23412000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
201427000
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3700000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7500000
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3600000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7100000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
7464000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
14919000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
14319000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
12385000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
12245000
CY2022Q2 cyrx Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
90008000
CY2022Q2 cyrx Future Amortization Of Finite Lived Intangible Assets
FutureAmortizationOfFiniteLivedIntangibleAssets
151340000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.644
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1734000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
28022000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
44442000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1715000
CY2022Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
634000
CY2022Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
11408000
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
12673000
CY2022Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
405436000
CY2021Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
404171000
CY2022Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
872000
CY2021Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
853000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1268000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
385000
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
1506000
CY2021Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
1046000
us-gaap Interest Expense Debt
InterestExpenseDebt
3002000
us-gaap Interest Expense Debt
InterestExpenseDebt
2100000
CY2022Q2 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
117.59
CY2022Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
100000000.0
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3159000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3011000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.808
cyrx Lessee Option To Extend
LesseeOptionToExtend
P5Y
us-gaap Operating Lease Cost
OperatingLeaseCost
2530000
us-gaap Operating Lease Cost
OperatingLeaseCost
1997000
us-gaap Operating Lease Payments
OperatingLeasePayments
2444000
us-gaap Operating Lease Payments
OperatingLeasePayments
1771000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2103000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5440000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P13Y8M12D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y7M6D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.082
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.051
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2161000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4307000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3782000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Dividends Paidinkind
DividendsPaidinkind
4000000.0
CY2021 us-gaap Dividends Paidinkind
DividendsPaidinkind
8200000
CY2020Q4 cyrx Deemed Dividend
DeemedDividend
39500000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
20680000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
23762000
CY2022Q2 cyrx Current Portion Of Operating Lease Liability
CurrentPortionOfOperatingLeaseLiability
2656000
CY2022Q2 cyrx Non Current Portion Of Operating Lease Liability
NonCurrentPortionOfOperatingLeaseLiability
21106000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
23762000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
11500
CY2022Q1 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
100000000.0
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
1341571
us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
24.84
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
33300000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 cyrx Preferred Stock Convertible Conversion Cost
PreferredStockConvertibleConversionCost
1800000
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17703975
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.021
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.036
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.005
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.009
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.675
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.786
us-gaap Share Based Compensation
ShareBasedCompensation
7015000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
5258000
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
4024000
us-gaap Share Based Compensation
ShareBasedCompensation
9383000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.30
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3100000
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
19600000

Files In Submission

Name View Source Status
0001410578-22-002045-index-headers.html Edgar Link pending
0001410578-22-002045-index.html Edgar Link pending
0001410578-22-002045.txt Edgar Link pending
0001410578-22-002045-xbrl.zip Edgar Link pending
cyrx-20220630.xsd Edgar Link pending
cyrx-20220630x10q.htm Edgar Link pending
cyrx-20220630x10q004.jpg Edgar Link pending
cyrx-20220630x10q_htm.xml Edgar Link completed
cyrx-20220630xex31d1.htm Edgar Link pending
cyrx-20220630xex31d2.htm Edgar Link pending
cyrx-20220630xex32d1.htm Edgar Link pending
cyrx-20220630_cal.xml Edgar Link unprocessable
cyrx-20220630_def.xml Edgar Link unprocessable
cyrx-20220630_lab.xml Edgar Link unprocessable
cyrx-20220630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending